Curated News
By: NewsRamp Editorial Staff
January 29, 2026
Soligenix Advances Novel CTCL Therapy with Visible Light Treatment
TLDR
- Soligenix's HyBryte therapy offers a competitive edge by providing a safer, targeted treatment for early-stage CTCL with statistically significant efficacy over traditional phototherapies.
- HyBryte works as a visible light-activated photodynamic therapy using synthetic hypericin to target malignant T-cells in skin while minimizing damage to healthy tissue.
- This therapy improves patient outcomes for a difficult-to-diagnose cancer, offering hope and better quality of life for those with rare diseases like CTCL.
- Soligenix's novel approach uses visible light instead of ultraviolet radiation, creating a safer photodynamic therapy that's showing promising results in clinical trials.
Impact - Why it Matters
This development matters because CTCL represents a significant unmet medical need with limited treatment options, particularly in early stages where accurate diagnosis is notoriously difficult. Traditional phototherapies using ultraviolet light carry substantial long-term risks, including skin damage and increased cancer risk with cumulative exposure. HyBryte's visible light activation offers a potentially safer alternative that could transform treatment paradigms for this rare cancer. For patients, this could mean more effective lesion reduction with fewer side effects, improving quality of life and potentially changing disease progression. The broader implications extend to Soligenix's pipeline, which includes treatments for other inflammatory conditions and public health threats, suggesting the company's technology platform could benefit multiple patient populations facing limited therapeutic options.
Summary
Cutaneous T-cell lymphoma (CTCL), recognized as one of the most difficult cancers to diagnose in early stages, may soon have a promising new treatment option. Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing HyBryte™ (synthetic hypericin), a novel photodynamic therapy designed specifically for early-stage CTCL. Unlike traditional ultraviolet-based treatments that carry long-term safety risks, HyBryte is activated by visible light in the red-yellow spectrum, allowing targeted treatment of malignant T-cells while minimizing damage to surrounding healthy tissue. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions, offering hope for patients facing this challenging rare disease.
Soligenix's efforts to address critical gaps in rare disease treatment extend beyond CTCL. The company's Specialized BioTherapeutics business segment is also developing synthetic hypericin for psoriasis, as well as first-in-class innate defense regulator technology for inflammatory diseases including oral mucositis in head and neck cancer and Behçet's disease. Meanwhile, their Public Health Solutions segment includes vaccine programs targeting ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 through their CiVax™ candidate, all incorporating their proprietary ThermoVax® heat stabilization platform technology. These programs have received support from government agencies including NIAID, DTRA, and BARDA.
The news about Soligenix's progress was reported by NetworkNewsWire (NNW), a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides financial news distribution and corporate communications solutions. NNW offers access to wire solutions through InvestorWire, article syndication to over 5,000 outlets, enhanced press release services, and social media distribution to millions of followers. For those interested in following Soligenix's developments, the company maintains a newsroom at https://ibn.fm/SNGX, and additional information can be found on their website at www.Soligenix.com. The full article detailing Soligenix's CTCL treatment advancements is available at https://.nnw.fm/aN4y7 for readers seeking comprehensive coverage of this important medical breakthrough.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Advances Novel CTCL Therapy with Visible Light Treatment
